Prostate cancer remains one of the most pressing global health challenges, ranking as the second most common cancer among men. While early-stage disease is often treatable, advanced forms—particularly metastatic castration-resistant prostate cancer (mCRPC)—continue to present formidable barriers to effective therapy.
Recent research highlights the transcription factor SOX2 as a central player in tumor growth, therapy resistance, and disease progression.
SOX2 regulates the behavior of cancer stem and progenitor cells, driving processes such as uncontrolled cell proliferation, resistance to programmed cell death, and epithelial-mesenchymal transition (EMT)—a mechanism that promotes tumor invasion and metastasis. Elevated SOX2 expression has been consistently linked to aggressive disease and poorer patient outcomes.
A critical feature of SOX2 is its role in tumor lineage plasticity, which enables cancer cells to adapt under therapeutic pressure. This adaptability often contributes to the emergence of neuroendocrine prostate cancer (NEPC), an aggressive variant with limited treatment options.
At the molecular level, SOX2 functions within a complex regulatory network, interacting with transcription factors, non-coding RNAs, and epigenetic regulators. It is deeply embedded in major signaling pathways—including PI3K/AKT, Hedgehog, Wnt/β-catenin, and TGF-β—that sustain cancer stem cell properties and fuel disease progression.
Upstream regulators such as BRN2, TRIB2, and NRP2, along with downstream effectors like LSD1, H19, SPINK1, and ASCL1, collectively reinforce SOX2’s influence on tumor aggressiveness.
SOX2 also plays a pivotal role in treatment resistance. It supports chemotherapy resistance by inducing reversible dormancy in cancer cells and activating survival mechanisms.
Additionally, it contributes to resistance against nuclear hormone receptor signaling inhibitors by altering cell cycle regulation and glucocorticoid receptor expression. This makes SOX2 a major obstacle in achieving long-term treatment success for advanced prostate cancer.
Targeting SOX2 represents a promising therapeutic frontier. Potential strategies include disrupting its protein-protein interactions, modulating upstream or downstream signaling networks, and developing selective small-molecule inhibitors.
However, researchers caution that because SOX2 is also essential for normal tissue regeneration, treatments must carefully balance efficacy with safety.
As scientific understanding deepens, strategies aimed at controlling SOX2 could open the door to more precise and durable therapies, offering renewed hope for patients facing the most aggressive forms of prostate cancer.
READ MORE
